Abstract Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely initiation of appropriate treatment for aHUS. Recent clinical and molecular findings have resulted in several proposed classifications and definitions of thrombotic microangiopathy and aHUS. Based on recent advances in this field and the emerging international consensus to exclude secondary TMAs from the definition of aHUS, we have redefined aHUS and proposed diagnostic algorithms, differential diagnosis, and therapeutic strategies for aHUS.
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Introduction
Thrombotic microangiopathy (TMA) is a pathophysiological process characterized by the triad of microangiopathic hemolytic anemia (MAHA), consumptive thrombocytopenia, and platelet-mediated microvascular occlusion, leading to organ failure. Classic forms of TMA include hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic
In 2014, Japanese Society of Nephrology and Japan Pediatric Society established the Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan, which published ''Clinical Guides for Atypical Hemolytic Uremic Syndrome in Japan'' in the Japanese Journal of Nephrology, 2016;58(2), p 62-75. This is the English version of that report. Chairman is Shoji Kagami, MD. PhD. This article has been co-published in Pediatrics International.
This article is a co-publication of Japanese Society of Nephrology and Japan Pediatric Society. purpura (TTP). TMAs caused by Shiga toxin-producing Escherichia coli (STEC) are termed STEC-HUS, while TMAs caused by severely reduced activity (levels less than 10 % of normal) of a disintegrin-like metalloproteinase with thrombospondin type 1 repeat motifs 13 (ADAMTS13) are termed TTP.
Approximately 90 % of patients presenting with HUS symptoms have STEC infection with bloody diarrhea. The remaining 10 % do not present with diarrhea and their samples are negative for Shiga toxins; such cases were previously classified as diarrhea-negative HUS (D(-)HUS). In 1981, the first case of D(-)HUS accompanied by complement factor H (CFH) deficiency was reported [1] . Warwicker et al. suggested CFH gene mutations as a possible cause of HUS in a linkage analysis study performed in 1998 [2] , one of the earliest works to propose genetic involvement in atypical HUS (aHUS). Subsequently, a series of studies indicated that aHUS pathogenesis involved genetic abnormalities of the complements, such as C3, complement factor B (CFB), complement factor I (CFI), membrane cofactor protein (MCP or CD46), and thrombomodulin (THBD). In addition, an acquired form of aHUS with positive anti-CFH antibodies has been identified.
Patients with aHUS have also been reported in Japan [3] , and a series of cases prompted the Japanese Society of Nephrology and the Japan Pediatric Society to jointly develop the aHUS diagnostic criteria in 2013 [4, 5] . These criteria broadly defined aHUS as a TMA condition unrelated to STEC-HUS or TTP; thus, the definition included aHUS with complement regulation abnormality and TMA with coexisting diseases (secondary TMA; also called other TMA). However, the international consensus to exclude secondary TMAs from the definition of aHUS [6] [7] [8] suggested the need to revise the 2013 edition. This article explains the diagnosis and treatment guides for aHUS, which have incorporated diagnostic algorithms and therapeutic recommendations to assist in clinical practice.
Definitions of TMA and aHUS
Originally, TMA was used to describe pathologic conditions involving systemic microvascular thrombosis and endothelial injury. Currently, TMA also refers to the clinical conditions with the triad of MAHA, consumptive thrombocytopenia, and platelet-mediated microvascular occlusion, leading to organ failures. Common forms of TMA include TTP, STEC-HUS, complement-related aHUS, and secondary TMA. Different types of TMA cause thrombosis in preferential organs, and renal impairment is the most frequent with STEC-HUS and aHUS.
There is currently no international consensus regarding the classification of diseases under TMA. According to the definition of the aHUS diagnostic criteria jointly proposed by the Japanese Society of Nephrology and the Japan Pediatric Society in 2013, aHUS involved the triad of MAHA, thrombocytopenia, and acute kidney failure in the absence of Shiga toxins and TTP [4, 5] .
Quoting the diagnostic criteria established by the UK aHUS Rare Disease Group, Scully and Goodship [7] proposed to exclude the following from aHUS: STEC-HUS, TTP, and secondary TMAs resulting from drugs, infection, transplantation, cobalamin deficiency, systemic lupus erythematosus, antiphospholipid syndrome, scleroderma, and other causes.
The definitions of aHUS and TMA have been considerably revised in the current aHUS clinical guides, based on findings reported by several publications [7] [8] [9] . Specifically, aHUS associated with congenital and acquired ''complement regulation abnormality'', as defined in the 2013 version, has been termed ''aHUS (complement-mediated HUS)'' in the current edition. In addition, TMAs arising from other causes have been defined as ''secondary TMAs.'' More specifically, aHUS defined in the current version relates to one of the following: 
Epidemiology
The exact incidence rates of aHUS are unknown. It is estimated that 2 per million adults and 3.3 per million children develop aHUS each year [10] . Approximately 40 % of patients who are newly diagnosed with aHUS are under 18 years of age [9, 11] . A one-year prospective study conducted in the United Kingdom reported that the incidence rate was 0.4 patients per million population [12] . In Japan, current estimates suggest that 100 to 200 patients are diagnosed with aHUS.
Etiology and pathophysiology
Complement-mediated HUS is caused by dysregulation of the alternative pathway of the complement system. The genetic causes of aHUS can be divided into loss-of-function and gain-of-function mutations. Loss-of-function mutations relate to the CFH, CFI, CD46, and THBD genes. Anti-CFH antibody also results in CFH dysfunction. Gainof-function mutations relate to the CFB and C3 genes. Loss-of-function and gain-of-function mutations both cause hyperactivation of the alternative complement pathway, which in turn induces aHUS by triggering endothelial damage and platelet aggregation. Anti-CFH autoantibodies have been detected in approximately 10 % of patients with aHUS [13] . These antibodies bind to the C-terminal domain of CFH and impair CFH-mediated cell surface protection by interfering with the interaction between CFH and its surface ligands.
Recent genetic studies of patients with TMA have identified abnormalities in the THBD, DGKE, and PLG encoding components of the coagulation and fibrinolytic pathways [14, 15] . However, the details of the involvement of these mutations in TMA pathogenesis remain to be clarified. While THBD is a key mediator of anticoagulant response, it also induces C3b inactivation by binding to C3b or CFH. In the current clinical guides, patients with THBD, DGKE, and PLG abnormalities are categorized as having aHUS.
Diagnosis Clinical manifestations
According to a UK national survey, the onset of many cases of aHUS is either idiopathic or secondary to infection and other disease triggers [16] . Similar to STEC-HUS, aHUS is frequently accompanied by hemolytic anemia, thrombocytopenia, and renal failure. The clinical manifestations may also include central neuropathy, cardiac failure, respiratory disorders, enterocolitis, hypertension, and other conditions affecting multiple organs or systems. Patients with aHUS may present with ischemic enterocolitis and other gastrointestinal problems. In addition, aHUS may be precipitated by microbial or viral infections of the digestive system. Therefore, attention should be paid to the fact that the presence of diarrhea does not exclude the diagnosis of aHUS [16] .
Clinical diagnostic criteria
Patients with TMA are clinically diagnosed with aHUS if the following diagnoses can be excluded: STEC-HUS, TTP, TMA secondary to metabolism-related, infection, drug-induced, autoimmune diseases, malignant tumors, hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, transplantation, or other known causes. TMA typically, but not necessarily, involves the following conditions:
1. MAHA with hemoglobin levels below 10 g/dL. In addition to blood hemoglobin levels, elevation of serum lactate dehydrogenase (LDH) level, notable decrease of serum haptoglobin level, and the presence of schistocytes on a peripheral blood smear should be taken into consideration to confirm the diagnosis of MAHA. Detection of schistocytes is not a necessary criterion for diagnosis of MAHA. 2. Thrombocytopenia with platelet counts less than 150,000/lL [9] . 3. Acute kidney injury (AKI). In pediatric patients, AKI is defined as serum creatinine levels at least 1.5 times the upper limit of the age-and sex-specific pediatric reference range defined by the Japanese Society for Pediatric Nephrology [17] . For adult patients, the diagnosis of AKI should be made according to wellestablished diagnostic guidelines [18] .
Differential diagnosis
Patients with TMA should be clinically diagnosed with aHUS after confirming that they do not meet the criteria for the following: first, STEC-HUS or TTP, and then, TMA secondary to known causative underlying conditions [7, 19] . It should be noted that some cases of secondary TMA have been reported to have complement gene mutations and anti-CFH antibodies. Future research should investigate the extent of the involvement of abnormal complement activation in the etiology of secondary TMA, the proportion of patients with complement gene mutations among the population with secondary TMA, and the effectiveness of eculizumab for treating secondary TMA. Clinicians should strongly suspect aHUS if the patient's family history includes individuals with the following diagnoses: aHUS; HUS, TTP, or TMA in the era when aHUS was not well recognized; or renal failure of unknown cause. [25] . In addition to pneumococcal infection, infections with human immunodeficiency virus (HIV), influenza A H1N1 virus, hepatitis C virus, and cytomegalovirus, as well as pertussis, varicella, and severe streptococcal infection, have been reported to cause TMA [16, 26, 27] . Attention should be paid to the cases where infections with influenza virus and other infections often trigger the onset of aHUS [28] .
• Pregnancy-induced HELLP syndrome and eclampsia. HELLP syndrome and eclampsia usually resolve quickly after delivery. However, cases of TTP and aHUS triggered by pregnancy have been reported in the literature. In a cohort study, patients with aHUS developed HELLP syndrome primarily postpartum [29] ; however, the incidence of aHUS among patients with HELLP syndrome or postpartum HELLP syndrome is unknown.
• Drug-induced TMA. Anti-tumor agents, antiplatelet drugs, immunosuppressive agents, and other medications may cause TMA (Table 1 ) [30] . Agents suspected of causing TMA should be tapered or discontinued wherever possible.
• Acute pancreatitis. Acute pancreatitis is a possible or probable precipitating event for TMA episodes [31] . In a review of seven cases of TMA precipitated by acute pancreatitis, patients responded well to therapeutic plasma exchange [32] .
• Post-transplant TMA subsequent to hematopoietic stem cell or organ transplantation. Posttransplant TMA following hematopoietic stem cell transplantation has been widely documented. In patients with post-transplant TMA, ADAMTS13 activities usually do not fall below 10 % of normal, and plasma exchange is not very effective. Typical interventions include discontinuation or dose reduction of immunosuppressive calcineurin inhibitors [33] . Recent research revealed a high prevalence of anti-CFH autoantibodies in pediatric patients with hematopoietic stem cell transplantassociated TMA [34] ; however, the involvement of complement dysregulation in the pathogenesis of TMA following hematopoietic stem cell transplant requires further investigation.
Patients with end-stage renal disease due to aHUS who are undergoing kidney transplant are at high risk of TMA recurrence and graft loss. It is therefore advisable to conduct genetic testing preoperatively in prospective kidney recipients suspected of having aHUS. TMAs occurring subsequent to kidney transplant (de novo) involve new onset of aHUS, with complement abnormalities [35] , as well as transplant-induced TMA [30] . The clinical approaches for patients with aHUS undergoing kidney transplantation and TMA after kidney transplantation are beyond the scope of this guide; please see the current consensus [8] . The occurrence of TMA has been documented not only in patients with kidney transplants, but in those receiving liver, heart, lung, and small intestine transplants [36] .
Considerations concerning pediatric diagnosis
STEC-HUS should primarily be suspected in children with TMA aged 6 months or older who manifest severe bloody diarrhea, because STEC-HUS accounts for approximately 90 % of all pediatric TMA cases. Conditions that predispose pediatric patients to TMA, not accompanied by diarrhea or bloody stool include pneumococcal and other infections in infants, and systemic lupus erythematosus and antiphospholipid syndrome. When a pediatric patient is diagnosed with TMA, the physician should immediately examine the possibility of TTP and determine whether existing medical conditions or oral medications are causing TMA. If these possibilities are ruled out, the physician should initiate eculizumab therapy while continuing to investigate whether rarer etiologies are responsible for TMA.
Laboratory confirmation of aHUS diagnosis
Besides the laboratory data supporting the diagnosis of TMA mentioned above, low C3 and normal C4 levels strongly suggest activation of the alternative pathway, and hence aHUS. However, previous data show that low C3 levels are detected in approximately half of patients with aHUS, and normal C3 levels do not necessarily rule out its diagnosis. To establish a diagnosis of aHUS, several studies recommend analyses of CFH, CFI, and CFB levels, and leukocyte expression levels of CD46 in addition to routine blood C3 and C4 measurements. However, the levels of these alternative complement molecules do not necessarily lead to the diagnosis of aHUS [6] . Quantitative hemolytic assay protocols using sheep erythrocytes are highly sensitive methods for detecting patients with genetic CFH abnormalities and anti-CFH antibodies [37, 38] . However, these protocols are still not practical for use in routine clinical settings. Urological examination in many patients with aHUS shows hematuria and proteinuria. Confirmatory diagnosis of aHUS requires genetic testing for known causative genes and analysis of anti-CFH antibodies. However, the absence of causative genetic mutations does not always exclude the diagnosis of aHUS, because approximately 40 % of patients show no known genetic abnormalities.
Physicians caring for patients with suspected aHUS in Japan are advised to contact the Division of Nephrology and Endocrinology, University of Tokyo Hospital (ahusoffice@umin.ac.jp), which will conduct hemolytic assay, anti-CFH antibody screening and genetic assays in collaboration with the National Cerebral and Cardiovascular Center, Research Institute, Osaka, Japan. These researches are supported as the government-subsidized program, ''Observational Study of Atypical Hemolytic Uremic Syndrome in Japan''.
Treatments Therapeutic considerations
Since the 1980s, plasma exchange therapy has been the mainstay method for management of aHUS. This therapy aims to eliminate abnormal complement regulatory proteins and anti-CFH antibodies, while supplementing normal complement regulatory proteins. Eculizumab is a humanized monoclonal antibody that binds to C5 complement protein. Eculizumab suppresses C5 cleavage to C5a and C5b and thereby prevents the production of the membrane attack complement complex (MAC).
In practical terms, when a patient presents with TMA and is negative for STEC-HUS and invasive pneumococcal infection (the latter of which is not indicated for plasma exchange), the treating physician should start the empirical treatments described below, while continuing diagnostic efforts. Physicians should also pay attention to systemic management such as fluid and electrolyte control, blood pressure control, and supportive therapies for AKI.
If the physician considers plasma exchange appropriate, it should be started immediately. Daily sessions followed by gradual tapering of the plasma therapy are recommended. Plasma infusion may be implemented in pediatric patients in whom plasma exchange is technically difficult to perform, as well as in situations where plasma exchange cannot be performed. The tapering of the plasma therapy will generally be based on improvements in platelet count, LDH and hemoglobin levels [39] . Although plasma infusion and plasma exchange can achieve hematological remission in approximately 70 % of patients with aHUS, long-term outcomes include high incidences of TMA recurrence, progression to end-stage renal failure, and death [40] .
If the patient is clinically diagnosed with aHUS after STEC-HUS, and if TTP and secondary TMA are ruled out, the physician should consider eculizumab therapy [7] . Eculizumab is recommended in the early stages of treatment of pediatric patients with clinically diagnosed aHUS because pediatric patients have a lower incidence of secondary TMA than adults and a higher rate of complications related to catheterization for plasma exchange and plasma infusion [8] .
Decreased platelet counts observed in patients with aHUS usually resolve after 1 to 2 weeks of eculizumab therapy [41] [42] [43] .
In anti-CFH antibody-positive patients, plasma exchange combined with immunosuppressants or steroids, as compared to plasma exchange alone, yielded better outcomes with reduced antibody titers [11] . Eculizumab may be considered for treating aHUS accompanied by extra-renal organ injury [8] .
Warnings and precautions for eculizumab use
Eculizumab has been shown to elevate the risk of meningococcal infection, and patients should be immunized with meningococcal vaccine at least two weeks prior to receiving eculizumab. If situations require immediate eculizumab administration in a patient who has not been immunized with meningococcal vaccine, the physician must administer appropriate prophylactic antibiotics.
Discontinuation of eculizumab
No expert consensus has been reached regarding the timing of eculizumab withdrawal after achievement of remission.
One study reviewed 20 cases of aHUS involving eculizumab therapy discontinuation [8] . Patients with CFH mutations and anti-CFH antibody-positive patients had a higher rate of recurrence. However, among patients with CD46 or CFI mutations and those without known causative genes, no recurrence was observed during the study period. In a similar review of 24 patients who terminated eculizumab therapy [44] , the incidence rate was 25 %, and recurrences were noted more frequently in patients with CFH mutation and those positive for anti-CFH antibodies. Available vaccines are insufficient for completely preventing meningococcal and other types of infections in patients receiving eculizumab. Eculizumab therapy requires patients to visit the hospital once every two weeks, a requirement that considerably affects their quality of life. Long-term repeated intravenous administration often leads to compromised vascular access. In addition, cost-benefit analyses should be considered for eculizumab, one of the most expensive drugs on the market. Future research on the relationship between genetic mutations and treatment outcomes, and markers for early detection of recurrence, will shed light on ways of overcoming these problems [8, 44] .
Outcome
The literature has reported gene-specific differences in response to therapeutic plasma exchange and in graft survival after kidney transplant [11] . While eculizumab therapy has been shown to improve treatment outcomes, its gene-specific outcomes are not well known.
